标题
Drugging p53 in cancer: one protein, many targets
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-10-11
DOI
10.1038/s41573-022-00571-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
- (2022) Shengliang Zhang et al. MOLECULAR CANCER RESEARCH
- Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy
- (2022) Yuling Xiao et al. Nature Communications
- Mutant p53: it’s not all one and the same
- (2022) Margaret C. Kennedy et al. CELL DEATH AND DIFFERENTIATION
- A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6-E6AP-p53 axis
- (2022) Jingwen Zhang et al. PHARMACOLOGICAL RESEARCH
- Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins
- (2022) Saptaparna Mukherjee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors
- (2022) Xiyao Cheng et al. Nature Communications
- Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients
- (2022) Ori Hassin et al. Nature Communications
- Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
- (2021) David A. Sallman et al. JOURNAL OF CLINICAL ONCOLOGY
- BRD4-mediated repression of p53 is a target for combination therapy in AML
- (2021) Anne-Louise Latif et al. Nature Communications
- Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
- (2021) Thomas Cluzeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting a neoantigen derived from a common TP53 mutation
- (2021) Emily Han-Chung Hsiue et al. SCIENCE
- Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
- (2021) Eduardo Alvarado-Ortiz et al. Frontiers in Cell and Developmental Biology
- Mutant p53 in cell-cell interactions
- (2021) Steven Pilley et al. GENES & DEVELOPMENT
- Organ chips, organoids and the animal testing conundrum
- (2021) Christine Horejs Nature Reviews Materials
- MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models
- (2021) Douglas D. Fang et al. Cell Death Discovery
- Tumor suppressor immune gene therapy to reverse immunotherapy resistance
- (2021) Sunil Chada et al. CANCER GENE THERAPY
- Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries
- (2021) Bo Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).
- (2021) Srdan Verstovsek et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.
- (2021) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment
- (2021) Martino Maddalena et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration
- (2021) Francisco J. Sánchez-Rivera et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function
- (2021) L. Palanikumar et al. Nature Communications
- Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity
- (2021) Xiaolei Zhou et al. Cancer Discovery
- p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi
- (2021) Xiaochao Tan et al. Science Advances
- Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
- (2021) Gihoon You et al. Vaccines
- Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
- (2021) Yi Li et al. International Journal of Oral Science
- Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)
- (2021) Oksana Degtjarik et al. Nature Communications
- Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens
- (2020) Parisa Malekzadeh et al. CLINICAL CANCER RESEARCH
- P53 and The Immune Response: 40 Years of Exploration—A Plan for the Future
- (2020) Arnold J. Levine INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- p53, cancer and the immune response
- (2020) Julianna Blagih et al. JOURNAL OF CELL SCIENCE
- Loss of p53 drives neuron reprogramming in head and neck cancer
- (2020) Moran Amit et al. NATURE
- MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia
- (2020) Pau Montesinos et al. Future Oncology
- Cas9 activates the p53 pathway and selects for p53-inactivating mutations
- (2020) Oana M. Enache et al. NATURE GENETICS
- An overview of development in gene therapeutics in China
- (2020) Dawei Wang et al. GENE THERAPY
- Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome
- (2020) Valeria Capaci et al. Nature Communications
- Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
- (2020) Regina Mirgayazova et al. Genes
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2
- (2020) Ana Barbosa et al. Cancers
- Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
- (2020) Shuo Chen et al. CANCER CELL
- Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
- (2020) Karen Yee et al. LEUKEMIA RESEARCH
- Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
- (2020) Shipeng He et al. Acta Pharmaceutica Sinica B
- Cancer therapeutic targeting using mutant–p53-specific siRNAs
- (2019) Ifeoma Ubby et al. ONCOGENE
- Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
- (2019) Parisa Malekzadeh et al. JOURNAL OF CLINICAL INVESTIGATION
- Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of both Normal and Tumor Tissues In Vivo
- (2019) Yuezhen Xue et al. CANCER RESEARCH
- Gene Therapy Leaves a Vicious Cycle
- (2019) Reena Goswami et al. Frontiers in Oncology
- Oral Idasanutlin in Patients with Polycythemia Vera
- (2019) John Mascarenhas et al. BLOOD
- COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms
- (2019) Antje Lindemann et al. CLINICAL CANCER RESEARCH
- Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
- (2019) Max D. Wellenstein et al. NATURE
- Mutant p53 improves cancer cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6
- (2019) Daria Sicari et al. ONCOGENE
- Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
- (2019) Lawrence A. Donehower et al. Cell Reports
- Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen
- (2019) Lionel Low et al. Nature Communications
- MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
- (2019) Douglas D. Fang et al. Journal for ImmunoTherapy of Cancer
- A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth
- (2019) Marta Celegato et al. CANCER LETTERS
- Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition
- (2019) Na Kong et al. Science Translational Medicine
- T-cell responses toTP53"hotspot" mutations and unique neoantigens expressed by human ovarian cancers
- (2018) Drew C Deniger et al. CLINICAL CANCER RESEARCH
- p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy
- (2018) Nicola R. Hardwick et al. CLINICAL CANCER RESEARCH
- Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy
- (2018) Yu Xia et al. HUMAN GENE THERAPY
- The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic
- (2018) Wei-Wei Zhang et al. HUMAN GENE THERAPY
- A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
- (2018) Hanjie Yi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons
- (2018) Maciej Dabrowski et al. MOLECULAR MEDICINE
- p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
- (2018) Robert J. Ihry et al. NATURE MEDICINE
- CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
- (2018) Emma Haapaniemi et al. NATURE MEDICINE
- Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
- (2018) Luis A. Carvajal et al. Science Translational Medicine
- USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells
- (2018) Achuth Padmanabhan et al. Nature Communications
- Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
- (2018) Tomer Cooks et al. Nature Communications
- Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor
- (2018) Sang-Soo Kim et al. OncoImmunology
- Abstract CT033: Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer
- (2018) Shannon N. Westin et al. CANCER RESEARCH
- Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53-MDM2 inhibitor HDM201
- (2018) Sébastien Jeay et al. CANCER RESEARCH
- Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
- (2018) Alberto A. Chiappori et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Mutant p53 as a guardian of the cancer cell
- (2018) Fiamma Mantovani et al. CELL DEATH AND DIFFERENTIATION
- Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
- (2018) Yangbing Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector
- (2017) Rodrigo Esaki Tamura et al. HUMAN GENE THERAPY
- Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53
- (2017) Xin Yu et al. MOLECULAR PHARMACOLOGY
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
- (2017) Kanaga Sabapathy et al. Nature Reviews Clinical Oncology
- Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/−mouse model
- (2017) Emilie A. Chapeau et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells
- (2017) Laure Bidou et al. RNA Biology
- Exploiting the p53 Pathway for Therapy
- (2017) Chit Fang Cheok et al. Cold Spring Harbor Perspectives in Medicine
- Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin
- (2017) Armin Wiegering et al. NEOPLASIA
- A surface charge-switchable and folate modified system for co-delivery of proapoptosis peptide and p53 plasmid in cancer therapy
- (2016) Si Chen et al. BIOMATERIALS
- A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
- (2016) Alice Soragni et al. CANCER CELL
- Stapled peptide design: principles and roles of computation
- (2016) Yaw Sing Tan et al. DRUG DISCOVERY TODAY
- Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study
- (2016) Kathleen F Pirollo et al. MOLECULAR THERAPY
- Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
- (2016) Alexis C. Komor et al. NATURE
- Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer
- (2016) Dawid Walerych et al. NATURE CELL BIOLOGY
- Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
- (2016) Åsa Fransson et al. Journal of Ovarian Research
- Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides
- (2016) Perry Tal et al. Oncotarget
- COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
- (2016) Kowthar Y. Salim et al. Oncotarget
- The Role of MDM2 Amplification and Overexpression in Tumorigenesis
- (2016) Jonathan D. Oliner et al. Cold Spring Harbor Perspectives in Medicine
- p53 in the DNA-Damage-Repair Process
- (2016) Ashley B. Williams et al. Cold Spring Harbor Perspectives in Medicine
- Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
- (2016) Vladimir J. N. Bykov et al. Frontiers in Oncology
- Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis
- (2015) Chantal Bou-Hanna et al. CANCER LETTERS
- Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53
- (2015) Shengliang Zhang et al. CANCER RESEARCH
- Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
- (2015) M. Andreeff et al. CLINICAL CANCER RESEARCH
- The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
- (2015) J. Canon et al. MOLECULAR CANCER THERAPEUTICS
- A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme
- (2015) Sang-Soo Kim et al. Nanomedicine-Nanotechnology Biology and Medicine
- Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
- (2015) E. M. Alexandrova et al. NATURE
- Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding
- (2015) GuoZhen Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner
- (2015) Carlotta Giorgi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
- (2015) N Mohell et al. Cell Death & Disease
- Reactivation of p53 via MDM2 inhibition
- (2015) E S Kim et al. Cell Death & Disease
- Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial
- (2014) Yi Li et al. BMC Medicine
- Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
- (2014) M N Saha et al. BRITISH JOURNAL OF CANCER
- Identification and Characterization of Small Molecules That Inhibit Nonsense-Mediated RNA Decay and Suppress Nonsense p53 Mutations
- (2014) L. Martin et al. CANCER RESEARCH
- p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
- (2014) N. R. Hardwick et al. CLINICAL CANCER RESEARCH
- Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
- (2014) Daqing Sun et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drugging the p53 pathway: understanding the route to clinical efficacy
- (2014) Kian Hoe Khoo et al. NATURE REVIEWS DRUG DISCOVERY
- p53 gene therapy of human breast carcinoma: using a transferrin-modified silica nanoparticles
- (2014) Chandrababu Rejeeth et al. Breast Cancer
- RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38
- (2014) A Weilbacher et al. Cell Death & Disease
- A Versatile Platform to Analyze Low-Affinity and Transient Protein-Protein Interactions in Living Cells in Real Time
- (2014) Yao-Cheng Li et al. Cell Reports
- A cationic cholesterol based nanocarrier for the delivery of p53-EGFP-C3 plasmid to cancer cells
- (2013) Santosh K. Misra et al. BIOMATERIALS
- Randomized, controlled phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene therapy in treatment of oral cancer
- (2013) S Liu et al. CANCER GENE THERAPY
- Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
- (2013) Camelia Iancu-Rubin et al. EXPERIMENTAL HEMATOLOGY
- Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
- (2013) Neil Senzer et al. MOLECULAR THERAPY
- Small molecule induced reactivation of mutant p53 in cancer cells
- (2013) Xiangrui Liu et al. NUCLEIC ACIDS RESEARCH
- Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
- (2013) Yong S. Chang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
- (2013) K. Shchors et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
- (2013) Binh Vu et al. ACS Medicinal Chemistry Letters
- Allele-Specific p53 Mutant Reactivation
- (2012) Xin Yu et al. CANCER CELL
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
- (2012) Isabelle Ray-Coquard et al. LANCET ONCOLOGY
- Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2
- (2011) S. Textor et al. CANCER RESEARCH
- PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
- (2011) R. Zandi et al. CLINICAL CANCER RESEARCH
- Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer
- (2011) Ninke Leffers et al. INTERNATIONAL JOURNAL OF CANCER
- Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study
- (2011) Renee Vermeij et al. INTERNATIONAL JOURNAL OF CANCER
- Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
- (2011) Jie Xu et al. Nature Chemical Biology
- Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
- (2011) M Michaelis et al. Cell Death & Disease
- High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer
- (2010) Özcan Met et al. BREAST CANCER RESEARCH AND TREATMENT
- A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
- (2010) Federico Bernal et al. CANCER CELL
- Rescue of p53 Function by Small-Molecule RITA in Cervical Carcinoma by Blocking E6-Mediated Degradation
- (2010) C. Y. Zhao et al. CANCER RESEARCH
- Autophagy regulation by p53
- (2010) Maria Chiara Maiuri et al. CURRENT OPINION IN CELL BIOLOGY
- APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells
- (2010) Dina Ali et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
- (2010) Alberto A Chiappori et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides
- (2010) Célia Floquet et al. NUCLEIC ACIDS RESEARCH
- PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
- (2009) Jeremy M.R. Lambert et al. CANCER CELL
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer
- (2009) F. M. Speetjens et al. CLINICAL CANCER RESEARCH
- Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1 and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia
- (2009) J. Yang et al. MOLECULAR AND CELLULAR BIOLOGY
- Transcription-independent p53 apoptosis: an alternative route to death
- (2009) Daniel Speidel TRENDS IN CELL BIOLOGY
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
- (2009) M. Olivier et al. Cold Spring Harbor Perspectives in Biology
- The mitochondrial p53 pathway
- (2008) Angelina V. Vaseva et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
- (2008) Ashley R. Schneekloth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen
- (2008) M. M. Lauwen et al. CANCER RESEARCH
- Mutant p53 targeting by the low molecular weight compound STIMA-1
- (2008) Nicole Zache et al. Molecular Oncology
- Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway
- (2008) J. E. Kravchenko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
- (2008) F. M. Boeckler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started